2. Search Result
Search Result
Results for "

Xa

" in MedChemExpress (MCE) Product Catalog:

50

Inhibitors & Agonists

1

Fluorescent Dye

2

Biochemical Assay Reagents

8

Peptides

4

Isotope-Labeled Compounds

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10268S
    Betrixaban-d6

    		Factor Xa Cardiovascular Disease
    Betrixaban-d6 is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor[1].
    Betrixaban-d6
  • HY-119124
    Edoxaban M4

    D21-2393

    		 Drug Metabolite Metabolic Disease
    Edoxaban M4, an active metabolite of Edoxaban, shows reproducible, but concentration-dependent matrix effects. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor .
    Edoxaban M4
  • HY-115918
    XA-E

    Xanthoangelol E

    		 Others Infection
    XA-E is a compound purified from a methanol-ethyl acetate extract from A. keiskei. XA-E displays anti-ZIKV activity with an IC50 value of 22.0 µM .
    <em>XA</em>-E
  • HY-12605
    SAR107375

    		Thrombin Metabolic Disease
    SAR107375 is a potent and orally active dual thrombin and factor Xa inhibitor, with Ki values of 1 nM and 8 nM for factor Xa and thrombin, respectively .
    SAR107375
  • HY-10777
    EMD 495235

    		Factor Xa Cardiovascular Disease
    EMD 495235 is a potent and orally active coagulation factor Xa inhibitor with an IC50 of 5.5 nM and a Ki of 6.8 nM. EMD 495235 shows anticoagulant activities .
    EMD 495235
  • HY-50667S
    Apixaban-13C,d3

    BMS-562247-01-13C,d3

    		 Factor Xa Cardiovascular Disease
    Apixaban- 13C,d3 is a deuterium and 13C labeled Apixaban. Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively[1].
    Apixaban-13C,d3
  • HY-18660
    Ciraparantag

    PER977

    		 Factor Xa Cardiovascular Disease
    Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .
    Ciraparantag
  • HY-50667
    Apixaban
    5+ Cited Publications

    BMS-562247-01

    		 Factor Xa Cardiovascular Disease
    Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
    Apixaban
  • HY-76971
    Dechloro Rivaroxaban

    		Factor Xa Cardiovascular Disease
    Dechloro Rivaroxaban is a highly selective, orally active inhibitor of Factor Xa. Dechloro Rivaroxaban inhibits human free FXa with a Ki of 0.4 nM. Dechloro Rivaroxaban inhibits prothrombinase activity and fibrin-associated FXa activity with IC50s of 2.1 nM and 92 nM, respectively .
    Dechloro Rivaroxaban
  • HY-B0597
    Fondaparinux sodium
    3 Publications Verification

    Fondaparin sodium; SR-90107A

    		 Factor Xa Cardiovascular Disease
    Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.
    Fondaparinux sodium
  • HY-11091
    Razaxaban hydrochloride

    BMS 561389 hydrochloride; DPC 906 hydrochloride

    		 Factor Xa Thrombin Cardiovascular Disease
    Razaxaban hydrochloride (BMS 561389 hydrochloride) is a highly potent, selective and orally active factor Xa inhibitor with a Ki of 0.19 nM. Razaxaban hydrochloride exhibits excellent selectivity (>5000-fold) for factor Xa over other related serine proteases. Razaxaban hydrochloride is also a potent thrombin inhibitor with a Ki of 540 nM. Razaxaban hydrochloride has strongly antithrombotic activity .
    Razaxaban hydrochloride
  • HY-11090A
    DPC423

    		Factor Xa Cardiovascular Disease
    DPC423 is a highly potent, selective, and orally active factor Xa inhibitor with a Ki of 0.15 nM .
    DPC423
  • HY-P3126
    Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride

    		Factor Xa Others
    Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride is a factor Xa specific chromogenic substrate .
    Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride
  • HY-153829
    CH3OCO-D-CHA-Gly-Arg-pNA acetate

    		Factor Xa Cardiovascular Disease
    CH3OCO-D-CHA-Gly-Arg-pNA acetate is a chromogenic substrate for factor Xa .
    CH3OCO-D-CHA-Gly-Arg-pNA acetate
  • HY-B0597R
    Fondaparinux sodium (Standard)

    Fondaparin sodium (Standard); SR-90107A (Standard)

    		 Factor Xa Cardiovascular Disease Cancer
    Fondaparinux (sodium) (Standard) is the analytical standard of Fondaparinux (sodium). This product is intended for research and analytical applications. Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.
    Fondaparinux sodium (Standard)
  • HY-B0385
    Gabexate mesylate
    4 Publications Verification

    FOY

    		 Proteasome Factor Xa Inflammation/Immunology
    Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with Kis of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with Kis of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .
    Gabexate mesylate
  • HY-153817
    FXIa-IN-13

    		Factor Xa Cardiovascular Disease
    FXIa-IN-13 (example 1) is an Factor Xa inhibitor with antithrombotic activity. FXIa-IN-13 inhibits arteriovenous thrombosis in vivo and in vitro .
    FXIa-IN-13
  • HY-P4576
    Methoxycarbonyl-D-Nle-Gly-Arg-pNA

    		Factor Xa Others
    Methoxycarbonyl-D-Nle-Gly-Arg-pNA is a synthetic trypsin that can serve as a substrate for coagulation factors IXa (FIXa) and Xa (FXa) .
    Methoxycarbonyl-D-Nle-Gly-Arg-pNA
  • HY-19373
    RWJ-445167

    3DP-10017

    		 Thrombin Factor Xa Cardiovascular Disease
    RWJ-445167 (3DP-10017) is a dual inhibitor of thrombin and factor Xa with Ki of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.
    RWJ-445167
  • HY-10268
    Betrixaban
    4 Publications Verification

    PRT054021

    		 Factor Xa Cardiovascular Disease
    Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect .
    Betrixaban
  • HY-10268B
    Betrixaban hydrochloride

    PRT054021 hydrochloride

    		 Factor Xa Cardiovascular Disease
    Betrixaban (PRT054021) hydrochloride is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban hydrochloride shows antithrombotic effect .
    Betrixaban hydrochloride
  • HY-10268A
    Betrixaban maleate

    PRT054021 maleate

    		 Factor Xa Cardiovascular Disease
    Betrixaban (PRT054021) maleate is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban maleate shows antithrombotic effect .
    Betrixaban maleate
  • HY-W018781
    Benzamidine hydrochloride
    2 Publications Verification

    		 Ser/Thr Protease Cancer
    Benzamidine hydrochloride is a trypsin-like serine proteases with Kis of 20, 21, 97, 110, 320 and 750 μM against Tryptase, Trypsin, uPA, Factor Xa, Thrombin and tPA, respectively .
    Benzamidine hydrochloride
  • HY-50903
    Rivaroxaban
    Maximum Cited Publications
    14 Publications Verification

    BAY 59-7939

    		 Factor Xa Cardiovascular Disease Cancer
    Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM) .
    Rivaroxaban
  • HY-100655
    O-Desmethyl apixaban

    		Drug Metabolite Cardiovascular Disease
    O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01) . Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively .
    O-Desmethyl apixaban
  • HY-18660B
    Ciraparantag acetate

    PER977 acetate

    		 Factor Xa Cardiovascular Disease
    Ciraparantag (PER977) acetate is a thrombin and factor Xa inhibitor. Ciraparantag acetate is a broad-spectrum reversal agent for anticoagulants, including low molecular weight heparins, unfractionated heparins, and some direct oral anticoagulants, but not VKAs.
    Ciraparantag acetate
  • HY-17567A
    Heparin sodium salt
    10+ Cited Publications

    Sodium heparin; Sodium heparinate

    		 Thrombin Factor Xa Autophagy Cardiovascular Disease Cancer
    Heparin sodium salt (Sodium heparin) is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa. Heparin sodium salt significantly inhibits exosome-cell interactions.
    Heparin sodium salt
  • HY-W087937
    Benzamidine hydrochloride hydrate
    2 Publications Verification

    Benzenecarboximidamide hydrochloride hydrate

    		 Ser/Thr Protease Cancer
    Benzamidine (Benzenecarboximidamide) hydrochloride hydrate is a reversible competitive trypsin-like serine proteases inhibitor with Kis of 20, 21, 97, 110, 320 and 750 μM against Tryptase, Trypsin, uPA, Factor Xa, Thrombin and tPA, respectively .
    Benzamidine hydrochloride hydrate
  • HY-76948
    5-R-Rivaroxaban

    		Factor Xa Cardiovascular Disease
    5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
    5-R-Rivaroxaban
  • HY-50903S
    Rivaroxaban-d4
    1 Publications Verification

    BAY 59-7939-d4
    Rivaroxaban-d4 is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent，selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM)[1][2].
    Rivaroxaban-d4
  • HY-122592
    Zifaxaban

    		Factor Xa Cardiovascular Disease
    Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC50 of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research .
    Zifaxaban
  • HY-14853
    Darexaban

    YM150

    		 Factor Xa Ser/Thr Protease Cardiovascular Disease
    Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC50 of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects .
    Darexaban
  • HY-134686
    Edoxaban impurity 4

    		Factor Xa Thrombin Cardiovascular Disease
    Edoxaban impurity 4 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention .
    Edoxaban impurity 4
  • HY-17567C
    Heparin sodium salt (MW 15kDa)
    1 Publications Verification

    Sodium heparin (MW 15kDa); Sodium heparinate (MW 15kDa)

    		 Thrombin Factor Xa Autophagy Cardiovascular Disease
    Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa. Heparin sodium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa .
    Heparin sodium salt (MW 15kDa)
  • HY-114015
    APC-6860

    		Ser/Thr Protease Cancer
    APC-6860 is a trypsin-like serine proteases inhibitor with ki values of 0.21 and 0.44 μM for uPA and trypsin, respectively. APC-6860 has a selectivity ratio for tPA versus uPA of 80. APC-6860 has ki values of 0.1 and 0.082 μM for human and murine urokinases, respectively. APC-6860 can be used for the research of cancer .
    APC-6860
  • HY-150554
    Antitubercular agent-29

    		Bacterial Infection
    Antitubercular agent-29 (compound 6xa) is a potent agent resistant (DR) Mycobacterium tuberculosis (Mtb) inhibitor with MIC of 0.03 μg/mL against agent-susceptible (DS)-Mtb strains, MIC of 0.03-0.06 μg/mL against DR-Mtb strains, and favourable selectivity (SI>40) against Vero cells .
    Antitubercular agent-29
  • HY-10264
    Edoxaban
    5 Publications Verification

    DU-176

    		 Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .
    Edoxaban
  • HY-10264B
    Edoxaban tosylate monohydrate
    5 Publications Verification

    DU-176b monohydrate

    		 Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .
    Edoxaban tosylate monohydrate
  • HY-10264A
    Edoxaban tosylate
    5 Publications Verification

    DU-176b

    		 Factor Xa Thrombin Cardiovascular Disease Cancer
    Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research .
    Edoxaban tosylate
  • HY-10264C
    Edoxaban hydrochloride

    DU-176 hydrochloride

    		 Factor Xa Thrombin Cardiovascular Disease
    Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research .
    Edoxaban hydrochloride
  • HY-50667S1
    Apixaban-d3

    BMS-562247-01-d3

    		 Isotope-Labeled Compounds Others
    Apixaban-d3 (BMS-562247-01-d3)is the deuterium labeledApixaban(HY-50667) . Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .
    Apixaban-d3
  • HY-153480
    ARC19499

    BAX499

    		 Factor Xa Others
    ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
    ARC19499
  • HY-153480A
    ARC19499 sodium

    BAX499 sodium

    		 Factor Xa Others
    ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
    ARC19499 sodium
  • HY-109509
    Enoxaparin

    PK 10169; EnoXaparin sodium; Lovenox

    		 Factor Xa Thrombin SARS-CoV Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19 .
    Enoxaparin
  • HY-P2185
    NFF-3

    		MMP Others
    NFF-3, the peptide, is a selective MMP substrate. NFF-3 selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity .
    NFF-3
  • HY-P2185A
    NFF-3 TFA

    		MMP Others
    NFF-3 TFA, the peptide, is a selective MMP substrate. NFF-3 TFA selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 TFA is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 TFA with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity .
    NFF-3 TFA
  • HY-P6023
    D-Leu-Pro-Arg-Rh110-D-Pro

    		Factor Xa Cardiovascular Disease
    D-Leu-Pro-Arg-Rh110-D-Pro is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro can be used to detect FXIa activity .
    D-Leu-Pro-Arg-Rh110-D-Pro
  • HY-P6023B
    D-Leu-Pro-Arg-Rh110-D-Pro acetate

    		Factor Xa Cardiovascular Disease
    D-Leu-Pro-Arg-Rh110-D-Pro acetate is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro acetate consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro acetate can be used to detect FXIa activity .
    D-Leu-Pro-Arg-Rh110-D-Pro acetate
  • HY-P6023A
    D-Leu-Pro-Arg-Rh110-D-Pro TFA

    		Factor Xa Cardiovascular Disease
    D-Leu-Pro-Arg-Rh110-D-Pro TFA is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro TFA consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro TFA can be used to detect FXIa activity .
    D-Leu-Pro-Arg-Rh110-D-Pro TFA
  • HY-10264S
    Edoxaban-d6

    DU-176-d6

    		 Factor Xa Thrombin Cardiovascular Disease
    Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .
    Edoxaban-d6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: